BLA 021859 · Halozyme Therap
Hylenex Recombinant
Hyaluronidase Recombinant Human · Injection · Endoglycosidase
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jan 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Dec 2, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
155
39 Phase 3, 16 recruiting
FAERS reports
1,227
1,022 serious, 548 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 11, 2024.
1. Indications and Usage HYLENEX recombinant is an endoglycosidase indicated as an adjuvant in subcutaneous fluid administration for achieving hydration ( 1.1 ) to increase the dispersion and absorption of other injected drugs ( 1.2 ) in subcutaneous urography for improving resorption of radiopaque agents ( 1.3 ) 1.1. Subcutaneous Fluid Administration HYLENEX recombinant is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration. 1.2. Dispersion and Absorption of Injected Drugs HYLENEX recombinant is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs. 1.3. Subcutaneous Urography HYLENEX recombinant is indicated as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.
Mechanism: Hyaluronidase is a dispersion agent, which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue, and of certain specialized tissues, such as the umbilical cord and vitreous humor. Hyaluronic acid is also present in the capsules of type A and C hemolytic streptococci. Hyaluronidase hydrolyzes hyaluronic acid by splitting the glucosaminidic bond between C1 of an N-acetylglucosamine moiety and C4 of a glucuronic acid moiety. This temporarily decreases the viscosity of the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 2, 2005 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewLetterLabel
1 products under this application
- HYLENEX RECOMBINANT · HYALURONIDASE RECOMBINANT HUMAN 150 UNITS/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Hyaluronidase Recombinant Human" as an intervention, any sponsor and status, largest first.
- Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialPivotal-lookingRecruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT04566328 · 1,450 participants (planned) · Start Feb 24, 2021 · Primary completion Dec 31, 2027
Drug: Bortezomib; Daratumumab and Hyaluronidase-fihj and 2 more · For: Plasma Cell Myeloma; RISS Stage I Plasma Cell Myeloma; RISS Stage II Plasma Cell Myeloma
Sites: Anchorage, Alaska; Phoenix, Arizona; Tucson, Arizona · 647 sites in all
- S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationPivotal-lookingActive, not recruiting
SWOG Cancer Research NetworkResearch network
NCT04071457 · 1,100 participants (planned) · Start Aug 13, 2019 · Primary completion Sep 2032
Drug: Lenalidomide; Daratumumab/rHuPH20 · For: Multiple Myeloma
Sites: Anchorage, Alaska; Fairbanks, Alaska; Kingman, Arizona · 842 sites in all
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05296798 · 922 participants (planned) · Start Jul 18, 2022 · Primary completion Jun 15, 2028
Drug: Phesgo; Giredestrant and 4 more · For: Locally Advanced or Metastatic Breast Cancer
Sites: Tucson, Arizona; Los Angeles, California; Jacksonville, Florida · 198 sites in all
- Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaPivotal-lookingNot yet recruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT07887984 · 920 participants (planned) · Start Dec 23, 2026 · Primary completion Aug 1, 2033
Drug: Daratumumab and Recombinant Human Hyaluronidase; Lenalidomide and 5 more · For: Multiple Myeloma (MM)
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT07383441 · 718 participants (planned) · Start Jun 5, 2026 · Primary completion Jan 31, 2033
Drug: Axitinib; Cabozantinib and 7 more · For: Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8 and 1 more
Sites: Fayetteville, Arkansas; Jonesboro, Arkansas; Rogers, Arkansas · 41 sites in all
- A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SpreadPivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT04810078 · 681 participants · Start May 21, 2021 · Primary completion Jul 29, 2025
Drug: Nivolumab and rHuPH20; Nivolumab · For: Clear Cell Renal Cell Carcinoma
Sites: Chicago, Illinois; Buffalo, New York; West Reading, Pennsylvania · 89 sites in all
- A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaPivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05625399 · 579 participants · Start Mar 6, 2023 · Primary completion Aug 4, 2025
Drug: Nivolumab + Relatlimab; rHuPH20 · For: Melanoma
Sites: Phoenix, Arizona; Springdale, Arkansas; Los Angeles, California · 149 sites in all
- A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03277105 · 522 participants · Start Oct 27, 2017 · Primary completion Jun 27, 2019
Drug: Dara SC; Dara IV · For: Multiple Myeloma
Sites: Boston, Massachusetts; Charlotte, North Carolina; Camperdown, Australia · 146 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue305
- abdominal discomfort298
- alopecia294
- diarrhoea282
- asthenia281
- arthralgia280
- headache279
- hypertension279
- hypersensitivity278
- hepatic enzyme increased275
- contusion271
- asthma270
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 8 |
| 2006 | 22 |
| 2007 | 27 |
| 2008 | 8 |
| 2009 | 9 |
| 2010 | 6 |
| 2011 | 8 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 14 |
| 2015 | 45 |
| 2016 | 23 |
| 2017 | 31 |
| 2018 | 23 |
| 2019 | 29 |
| 2020 | 53 |
| 2021 | 67 |
| 2022 | 61 |
| 2023 | 110 |
| 2024 | 310 |
| 2025 | 232 |
| 2026 | 126 |
Recalls
1 FDA enforcement reports for this application.
Sep 11, 2024 · Class II · Terminated
cGMP Deviations: Temperature excursion
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Halozyme Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.